Search

Your search keyword '"Hölscher, Tobias"' showing total 252 results
Start Over Author "Hölscher, Tobias"
252 results on '"Hölscher, Tobias"'

1. The impact of multicentric datasets for the automated tumor delineation in primary prostate cancer using convolutional neural networks on 18F-PSMA-1007 PET

Author

Holzschuh, Julius C., Mix, Michael, Freitag, Martin T., Hölscher, Tobias, Braune, Anja, Kotzerke, Jörg, Vrachimis, Alexis, Doolan, Paul, Ilhan, Harun, Marinescu, Ioana M., Spohn, Simon K. B., Fechter, Tobias, Kuhn, Dejan, Gratzke, Christian, Grosu, Radu, Grosu, Anca-Ligia, and Zamboglou, C.

Published
2024
Full Text
View/download PDF

4. Erectile function preservation after salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: Five-year results of the SAKK 09/10 randomized phase 3 trial

Author

Zwahlen, Daniel R., Schröder, Christina, Holer, Lisa, Bernhard, Jürg, Hölscher, Tobias, Arnold, Winfried, Polat, Bülent, Hildebrandt, Guido, Müller, Arndt-Christian, Martin Putora, Paul, Papachristofilou, Alexandros, Schär, Corinne, Hayoz, Stefanie, Sumila, Marcin, Zaugg, Kathrin, Guckenberger, Matthias, Ost, Piet, Giovanni Bosetti, Davide, Reuter, Christiane, Gomez, Silvia, Khanfir, Kaouthar, Beck, Marcus, Thalmann, George N., Aebersold, Daniel M., and Ghadjar, Pirus

Published
2024
Full Text
View/download PDF

5. Prostatakarzinom: palliative Therapie

Author

Huber, Johannes, Fröhner, Michael, Wirth, Manfred, Kotzerke, Jörg, Brogsitter, Claudia, Hölscher, Tobias, Michel, Maurice Stephan, editor, W. Thüroff, Joachim, editor, Janetschek, Günter, editor, and Wirth, Manfred P., editor

Published
2023
Full Text
View/download PDF

6. Prostatakarzinom: kurative Therapie

Author

Fröhner, Michael, Wirth, Manfred, Baumann, Michael, Hölscher, Tobias, Michel, Maurice Stephan, editor, W. Thüroff, Joachim, editor, Janetschek, Günter, editor, and Wirth, Manfred P., editor

Published
2023
Full Text
View/download PDF

7. Deep learning based automated delineation of the intraprostatic gross tumour volume in PSMA-PET for patients with primary prostate cancer

Author

Holzschuh, Julius C., Mix, Michael, Ruf, Juri, Hölscher, Tobias, Kotzerke, Jörg, Vrachimis, Alexis, Doolan, Paul, Ilhan, Harun, Marinescu, Ioana M., Spohn, Simon K.B., Fechter, Tobias, Kuhn, Dejan, Bronsert, Peter, Gratzke, Christian, Grosu, Radu, Kamran, Sophia C., Heidari, Pedram, Ng, Thomas S.C., Könik, Arda, Grosu, Anca-Ligia, and Zamboglou, Constantinos

Published
2023
Full Text
View/download PDF

11. Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography–staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial

Author

Hölscher, Tobias, Baumann, Michael, Kotzerke, Jörg, Zöphel, Klaus, Paulsen, Frank, Müller, Arndt-Christian, Zips, Daniel, Koi, Lydia, Thomas, Christian, Löck, Steffen, Krause, Mechthild, Wirth, Manfred, and Lohaus, Fabian

Published
2022
Full Text
View/download PDF

12. Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries: A survey of the Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party on Radiation Oncology of the German Cancer Society (DKG-ARO)

Author

Shelan, Mohamed, Aebersold, Daniel M., Albrecht, Clemens, Böhmer, Dirk, Flentje, Michael, Ganswindt, Ute, Höcht, Stefan, Hölscher, Tobias, Müller, Arndt-Christian, Niehoff, Peter, Pinkawa, Michael, Schmidt-Hegemann, Nina-Sophie, Sedlmayer, Felix, Wolf, Frank, Zamboglou, Constantinos, Zips, Daniel, Wiegel, Thomas, and Ghadjar, Pirus

Published
2021
Full Text
View/download PDF

13. Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial

Author

Gut, P., Thum, P., Collon, J., Putora, P.M., Plasswilm, L., Sassowsky, M., Thalmann, G.N., Aebersold, D.M., Sumila, M., Kranzbühler, H., Zaugg, K., Papachristofilou, A., Zimmermann, F., Najafi, Y., Brown, M., Guckenberger, M., Wuttke, S., Reuter, C., Oehler, C., Zwahlen, D.R., Azinwi, N.C., Bosetti, D.G., Pesce, G., Tacacs, I., Bodis, S., Gomez, S., Khanfir, K., Behrensmeier, F., Beer, K., Messer, P., Hölscher, T., Baumann, M., Polat, B., Flentje, M., Lewitzki, V., Hildebrandt, G., Müller, A.C., Zips, D., Ghadjar, P., Wust, P., Budach, V., Ganswindt, U., Belka, C., Pinkawa, M., Eble, M.J., Berkovic, K., Stuschke, M., Ost, P., Vandaele, F., Ghadjar, Pirus, Hayoz, Stefanie, Bernhard, Jürg, Zwahlen, Daniel R., Hölscher, Tobias, Gut, Philipp, Polat, Bülent, Hildebrandt, Guido, Müller, Arndt-Christian, Plasswilm, Ludwig, Papachristofilou, Alexandros, Schär, Corinne, Sumila, Marcin, Zaugg, Kathrin, Guckenberger, Matthias, Ost, Piet, Reuter, Christiane, Bosetti, Davide G., Khanfir, Kaouthar, Gomez, Silvia, Wust, Peter, Thalmann, George N., and Aebersold, Daniel M.

Published
2021
Full Text
View/download PDF

14. Prostatakarzinom: palliative Therapie

Author

Huber, Johannes, primary, Fröhner, Michael, additional, Wirth, Manfred, additional, Kotzerke, Jörg, additional, Brogsitter, Claudia, additional, and Hölscher, Tobias, additional

Published
2022
Full Text
View/download PDF

16. Radiotherapy in nodal oligorecurrent prostate cancer

Author

Pinkawa, Michael, Aebersold, Daniel M., Böhmer, Dirk, Flentje, Michael, Ghadjar, Pirus, Schmidt-Hegemann, Nina-Sophie, Höcht, Stefan, Hölscher, Tobias, Müller, Arndt-Christian, Niehoff, Peter, Sedlmayer, Felix, Wolf, Frank, Zamboglou, Constantinos, Zips, Daniel, and Wiegel, Thomas

Published
2021
Full Text
View/download PDF

17. The impact of multicentric datasets for the automated tumor delineation in primary prostate cancer using convolutional neural networks on 18F-PSMA-1007 PET.

Author

Holzschuh, Julius C., Mix, Michael, Freitag, Martin T., Hölscher, Tobias, Braune, Anja, Kotzerke, Jörg, Vrachimis, Alexis, Doolan, Paul, Ilhan, Harun, Marinescu, Ioana M., Spohn, Simon K. B., Fechter, Tobias, Kuhn, Dejan, Gratzke, Christian, Grosu, Radu, Grosu, Anca-Ligia, and Zamboglou, C.

Subjects
CONVOLUTIONAL neural networks, VOLUMETRIC analysis, POSITRON emission tomography, PROSTATE cancer, STATISTICAL significance
Abstract

Purpose: Convolutional Neural Networks (CNNs) have emerged as transformative tools in the field of radiation oncology, significantly advancing the precision of contouring practices. However, the adaptability of these algorithms across diverse scanners, institutions, and imaging protocols remains a considerable obstacle. This study aims to investigate the effects of incorporating institution-specific datasets into the training regimen of CNNs to assess their generalization ability in real-world clinical environments. Focusing on a data-centric analysis, the influence of varying multi- and single center training approaches on algorithm performance is conducted. Methods: nnU-Net is trained using a dataset comprising 161 18F-PSMA-1007 PET images collected from four distinct institutions (Freiburg: n = 96, Munich: n = 19, Cyprus: n = 32, Dresden: n = 14). The dataset is partitioned such that data from each center are systematically excluded from training and used solely for testing to assess the model's generalizability and adaptability to data from unfamiliar sources. Performance is compared through a 5-Fold Cross-Validation, providing a detailed comparison between models trained on datasets from single centers to those trained on aggregated multi-center datasets. Dice Similarity Score, Hausdorff distance and volumetric analysis are used as primary evaluation metrics. Results: The mixed training approach yielded a median DSC of 0.76 (IQR: 0.64–0.84) in a five-fold cross-validation, showing no significant differences (p = 0.18) compared to models trained with data exclusion from each center, which performed with a median DSC of 0.74 (IQR: 0.56–0.86). Significant performance improvements regarding multi-center training were observed for the Dresden cohort (multi-center median DSC 0.71, IQR: 0.58–0.80 vs. single-center 0.68, IQR: 0.50–0.80, p < 0.001) and Cyprus cohort (multi-center 0.74, IQR: 0.62–0.83 vs. single-center 0.72, IQR: 0.54–0.82, p < 0.01). While Munich and Freiburg also showed performance improvements with multi-center training, results showed no statistical significance (Munich: multi-center DSC 0.74, IQR: 0.60–0.80 vs. single-center 0.72, IQR: 0.59–0.82, p > 0.05; Freiburg: multi-center 0.78, IQR: 0.53–0.87 vs. single-center 0.71, IQR: 0.53–0.83, p = 0.23). Conclusion: CNNs trained for auto contouring intraprostatic GTV in 18F-PSMA-1007 PET on a diverse dataset from multiple centers mostly generalize well to unseen data from other centers. Training on a multicentric dataset can improve performance compared to training exclusively with a single-center dataset regarding intraprostatic 18F-PSMA-1007 PET GTV segmentation. The segmentation performance of the same CNN can vary depending on the dataset employed for training and testing. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Online decision aid for patients with prostate cancer evaluated by 11 290 patients and 91 urologists in Germany.

Author

Huber, Johannes, Karschuck, Philipp, Valdix, Johanna, Thomas, Christian, Koch, Rainer, Ihrig, Andreas, Hölscher, Tobias, Krones, Tanja, Kessler, Elke, Kliesch, Sabine, Linné, Clemens, Enders, Paul, Michel, Maurice‐Stephan, Wülfing, Christian, and Groeben, Christer

Subjects
PROSTATE cancer patients, UROLOGISTS, HEALTH outcome assessment, WATCHFUL waiting, PATIENTS' attitudes
Abstract

Objective: To evaluate the nationwide online decision aid 'Entscheidungshilfe Prostatakrebs' (established in 2016, >11.000 users and 60 new users/week) for patients with non‐metastatic prostate cancer (PCa), from the perspective of patients and urologists. Patients and Methods: To provide personalised information, the tool collects most of the International Consortium for Health Outcomes Measurement standard set, personal preferences, psychological features, and a validated rating of the tool. To evaluate urologists' opinions, we developed a structured two‐page questionnaire. All data were collected anonymously. Results: From June 2016 to December 2020, 11 290 patients used the PCa decision aid. Their median (interquartile range [IQR]) age was 67 (61–72) years. The median (IQR) time from initial diagnosis to using the tool was 4 (3–7) weeks. In all, 87.7% of users reported high satisfaction. In a multivariable model, predictors for considering observation were higher knowledge, using the decision aid alone, lower oncological risk, normal erectile function, and respective personal preferences. Of 194 urologists, 91 (47%) had implemented the decision aid in their clinical practice. The urologists' mean (SD) satisfaction score (1 'very good'; 6 'unsatisfactory') with it was 1.45 (0.55), and 92% recommended it. Half of the urologists reported time savings. Conclusion: Patients and urologists report a very high level of acceptance and satisfaction with this online tool. It offers advantages in shared decision‐making and time efficiency. The usage of the decision aid might improve the adoption of active surveillance and watchful waiting when indicated. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10

Author

Ghadjar, Pirus, Hayoz, Stefanie, Bernhard, Jürg, Zwahlen, Daniel R., Stein, Jürgen, Hölscher, Tobias, Gut, Philipp, Polat, Bülent, Hildebrandt, Guido, Müller, Arndt-Christian, Putora, Paul Martin, Papachristofilou, Alexandros, Schär, Corinne, Dal Pra, Alan, Biaggi Rudolf, Christine, Wust, Peter, Aebersold, Daniel M., and Thalmann, George N.

Published
2018
Full Text
View/download PDF

31. Prostatakarzinom: Palliative Therapie

Author

Huber, Johannes, Brogsitter, Claudia, Kotzerke, Jörg, Hoelscher, Tobias, Baumann, Michael, Fröhner, Michael, Wirth, Manfred, Michel, Maurice Stephan, editor, Thüroff, Joachim W., editor, Janetschek, Günther, editor, and Wirth, Manfred, editor

Published
2016
Full Text
View/download PDF

32. Prostatakarzinom: Kurative Therapie

Author

Wirth, Manfred, Fröhner, Michael, Baumann, Michael, Hoelscher, Tobias, Michel, Maurice Stephan, editor, Thüroff, Joachim W., editor, Janetschek, Günther, editor, and Wirth, Manfred, editor

Published
2016
Full Text
View/download PDF

33. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy

Author

Ghadjar, Pirus, Aebersold, Daniel M., Albrecht, Clemens, Böhmer, Dirk, Flentje, Michael, Ganswindt, Ute, Höcht, Stefan, Hölscher, Tobias, Sedlmayer, Felix, Wenz, Frederik, Zips, Daniel, Wiegel, Thomas, and Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party Radiation Oncology of the German Cancer Society (DKG-ARO)

Published
2018
Full Text
View/download PDF

34. Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International Consensus

Author

Spohn, Simon K.B., primary, Draulans, Cédric, additional, Kishan, Amar U., additional, Spratt, Daniel, additional, Ross, Ashley, additional, Maurer, Tobias, additional, Tilki, Derya, additional, Berlin, Alejandro, additional, Blanchard, Pierre, additional, Collins, Sean, additional, Bronsert, Peter, additional, Chen, Ronald, additional, Pra, Alan Dal, additional, de Meerleer, Gert, additional, Eade, Thomas, additional, Haustermans, Karin, additional, Hölscher, Tobias, additional, Höcht, Stefan, additional, Ghadjar, Pirus, additional, Davicioni, Elai, additional, Heck, Matthias, additional, Kerkmeijer, Linda G.W., additional, Kirste, Simon, additional, Tselis, Nikolaos, additional, Tran, Phuoc T., additional, Pinkawa, Michael, additional, Pommier, Pascal, additional, Deltas, Constantinos, additional, Schmidt-Hegemann, Nina-Sophie, additional, Wiegel, Thomas, additional, Zilli, Thomas, additional, Tree, Alison C., additional, Qiu, Xuefeng, additional, Murthy, Vedang, additional, Epstein, Jonathan I., additional, Graztke, Christian, additional, Gao, Xin, additional, Grosu, Anca L., additional, Kamran, Sophia C., additional, and Zamboglou, Constantinos, additional

Published
2023
Full Text
View/download PDF

35. Detectability of Anatomical Changes With Prompt-Gamma Imaging: First Systematic Evaluation of Clinical Application During Prostate-Cancer Proton Therapy

Author

Berthold, Jonathan, primary, Pietsch, Julian, additional, Piplack, Nick, additional, Khamfongkhruea, Chirasak, additional, Thiele, Julia, additional, Hölscher, Tobias, additional, Janssens, Guillaume, additional, Smeets, Julien, additional, Traneus, Erik, additional, Löck, Steffen, additional, Stützer, Kristin, additional, and Richter, Christian, additional

Published
2023
Full Text
View/download PDF

36. Genomic classifiers in personalized prostate cancer radiation therapy approaches: a systematic review and future perspectives based on international consensus

Author

Tilki, Derya, Spohn, Simon K.B.; Draulans, Cédric; Kishan, Amar U.; Spratt, Daniel; Ross, Ashley; Maurer, Tobias; Berlin, Alejandro; Blanchard, Pierre; Collins, Sean; Bronsert, Peter; Chen, Ronald; Pra, Alan Dal; de Meerleer, Gert; Eade, Thomas; Haustermans, Karin; Hölscher, Tobias; Höcht, Stefan; Ghadjar, Pirus; Davicioni, Elai; Heck, Matthias; Kerkmeijer, Linda G.W.; Kirste, Simon; Tselis, Nikolaos; Tran, Phuoc T.; Pinkawa, Michael; Pommier, Pascal; Deltas, Constantinos; Schmidt-Hegemann, Nina-Sophie; Wiegel, Thomas; Zilli, Thomas; Tree, Alison C.; Qiu, Xuefeng; Murthy, Vedang; Epstein, Jonathan I.; Graztke, Christian; Gao, Xin; Grosu, Anca L.; Kamran, Sophia C.; Zamboglou, Constantinos, Koç University Hospital, School of Medicine, Tilki, Derya, Spohn, Simon K.B.; Draulans, Cédric; Kishan, Amar U.; Spratt, Daniel; Ross, Ashley; Maurer, Tobias; Berlin, Alejandro; Blanchard, Pierre; Collins, Sean; Bronsert, Peter; Chen, Ronald; Pra, Alan Dal; de Meerleer, Gert; Eade, Thomas; Haustermans, Karin; Hölscher, Tobias; Höcht, Stefan; Ghadjar, Pirus; Davicioni, Elai; Heck, Matthias; Kerkmeijer, Linda G.W.; Kirste, Simon; Tselis, Nikolaos; Tran, Phuoc T.; Pinkawa, Michael; Pommier, Pascal; Deltas, Constantinos; Schmidt-Hegemann, Nina-Sophie; Wiegel, Thomas; Zilli, Thomas; Tree, Alison C.; Qiu, Xuefeng; Murthy, Vedang; Epstein, Jonathan I.; Graztke, Christian; Gao, Xin; Grosu, Anca L.; Kamran, Sophia C.; Zamboglou, Constantinos, Koç University Hospital, and School of Medicine

Abstract

Current risk-stratification systems for prostate cancer (PCa) do not sufficiently reflect the disease heterogeneity. Genomic classifiers (GC) enable improved risk stratification after surgery, but less data exist for patients treated with definitive radiation therapy (RT) or RT in oligo-/metastatic disease stages. To guide future perspectives of GCs for RT, we conducted (1) a systematic review on the evidence of GCs for patients treated with RT and (2) a survey of experts using the Delphi method, addressing the role of GCs in personalized treatments to identify relevant fields of future clinical and translational research. We performed a systematic review and screened ongoing clinical trials on ClinicalTrials.gov. Based on these results, a multidisciplinary international team of experts received an adapted Delphi method survey. Thirty-one and 30 experts answered round 1 and round 2, respectively. Questions with ?75% agreement were considered relevant and included in the qualitative synthesis. Evidence for GCs as predictive biomarkers is mainly available to the postoperative RT setting. Validation of GCs as prognostic markers in the definitive RT setting is emerging. Experts used GCs in patients with PCa with extensive metastases (30%), in postoperative settings (27%), and in newly diagnosed PCa (23%). Forty-seven percent of experts do not currently use GCs in clinical practice. Expert consensus demonstrates that GCs are promising tools to improve risk-stratification in primary and oligo-/metastatic patients in addition to existing classifications. Experts were convinced that GCs might guide treatment decisions in terms of RT-field definition and intensification/deintensification in various disease stages. This work confirms the value of GCs and the promising evidence of GC utility in the setting of RT. Additional studies of GCs as prognostic biomarkers are anticipated and form the basis for future studies addressing predictive capabilities of GCs to optimize RT and, European Union (EU); Horizon 2020; Research and Innovation Programme; German Federal Ministry of Education and Research (BMBF); ERA PER Joint Funding Call 2019; A.T. acknowledges support from Cancer Research UK (C33589/A28284 and C7224/A28724 CRUK RadNet). This project represents independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. We thank Fotini Miltiadous for administrative support. ; Funding text 3: Disclosures: A.U.K. reports funding support from grant P50CA09213 from the Prostate Cancer National Institutes of Health Specialized Programs of Research Excellence and grant W81XWH-22-1-0044 from the Department of Defense, as well as grant RSD1836 from the Radiologic Society of North America, the STOP Cancer organization, the Jonsson Comprehensive Cancer Center, and the Prostate Cancer Foundation. C.Z. received funding from the Klaus Tschira foundation, Naslund Medical, and from the German Research Foundation. C.Z. received speaker fees from Johnson & Johnson and Novocure, all outside the submitted work. E.D. is an employee of Veracyte, manufacturer of Decipher. A.R. is a consultant and/or speaker for Astellas, Bayer, Pfizer, Blue Earth, Lantheus, Janssen, Tempus, and Veracyte. X.G. is on the consulting/advisory board for Bayer, Myovant, and Guardant Health.

Published
2023

37. Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy

Author

Klusa, Daria, primary, Lohaus, Fabian, additional, Franken, Andre, additional, Baumbach, Marian, additional, Cojoc, Monica, additional, Dowling, Paul, additional, Linge, Annett, additional, Offermann, Anne, additional, Löck, Steffen, additional, Hušman, Dejan, additional, Rivandi, Mahdi, additional, Polzer, Bernhard, additional, Freytag, Vera, additional, Lange, Tobias, additional, Neubauer, Hans, additional, Kücken, Michael, additional, Perner, Sven, additional, Hölscher, Tobias, additional, Dubrovska, Anna, additional, Krause, Mechthild, additional, Kurth, Ina, additional, Baumann, Michael, additional, and Peitzsch, Claudia, additional

Published
2023
Full Text
View/download PDF

38. Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy

Author

Klusa, Daria, Lohaus, Fabian, Franken, Andre, Baumbach, Marian, Cojoc, Monica, Dowling, Paul, Linge, Annett, Offermann, Anne, Löck, Steffen, Hušman, Dejan, Rivandi, Mahdi, Polzer, Bernhard Michael, Freytag, Vera, Lange, Tobias, Neubauer, Hans, Kücken, Michael, Perner, Sven, Hölscher, Tobias, Dubrovska, Anna, Krause, Mechthild, Kurth, Ina, Baumann, Michael, Peitzsch, Claudia, and Publica

Abstract

Ablative radiotherapy is a highly efficient treatment modality for patients with metastatic prostate cancer (PCa). However, a subset of patients does not respond. Currently, this subgroup with bad prognosis cannot be identified before disease progression. We hypothesize that markers indicative of radioresistance, stemness and/or bone tropism may have a prognostic potential to identify patients profiting from metastases-directed radiotherapy. Therefore, circulating tumor cells (CTCs) were analyzed in patients with metastatic PCa (n = 24) during radiotherapy with CellSearch, multicolor flow cytometry and imaging cytometry. Analysis of copy-number alteration indicates a polyclonal CTC population that changes after radiotherapy. CTCs were found in 8 out of 24 patients (33.3%) and were associated with a shorter time to biochemical progression after radiotherapy. Whereas the total CTC count dropped after radiotherapy, a chemokine receptor CXCR4-expressing subpopulation representing 28.6% of the total CTC population remained stable up to 3 months. At once, we observed higher chemokine CCL2 plasma concentrations and proinflammatory monocytes. Additional functional analyses demonstrated key roles of CXCR4 and CCL2 for cellular radiosensitivity, tumorigenicity and stem-like potential in vitro and in vivo. Moreover, a high CXCR4 and CCL2 expression was found in bone metastasis biopsies of PCa patients. In summary, panCK+ CXCR4+ CTCs may have a prognostic potential in patients with metastatic PCa treated with metastasis-directed radiotherapy.

Published
2023

40. PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives

Author

Zschaeck, Sebastian, Lohaus, Fabian, Beck, Marcus, Habl, Gregor, Kroeze, Stephanie, Zamboglou, Constantinos, Koerber, Stefan Alexander, Debus, Jürgen, Hölscher, Tobias, Wust, Peter, Ganswindt, Ute, Baur, Alexander D. J., Zöphel, Klaus, Cihoric, Nikola, Guckenberger, Matthias, Combs, Stephanie E., Grosu, Anca Ligia, Ghadjar, Pirus, and Belka, Claus

Published
2018
Full Text
View/download PDF

42. Intraindividual Comparison Between [18F] PSMA-1007 PET/CT and Multiparametric MRI for Radiotherapy Planning in Primary Prostate Cancer Patients

Author

Marinescu, Ioana M., primary, Spohn, Simon K. B., additional, Kiefer, Selina, additional, Bronsert, Peter, additional, Ceci, Lara, additional, Holzschuh, Julius, additional, Sigle, August, additional, Jilg, Cordula A., additional, Rühle, Alexander, additional, Sprave, Tanja, additional, Nicolay, Nils H., additional, Winzer, Robert, additional, Rehm, Jana, additional, Kotzerke, Jörg, additional, Hölscher, Tobias, additional, Grosu, Anca L., additional, Ruf, Juri, additional, Benndorf, Matthias, additional, and Zamboglou, Constantinos, additional

Published
2022
Full Text
View/download PDF

43. Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial

Author

Beck, Marcus, primary, Sassowsky, Manfred, additional, Schär, Sämi, additional, Mathier, Etienne, additional, Halter, Matthias, additional, Zwahlen, Daniel R., additional, Hölscher, Tobias, additional, Arnold, Winfried, additional, Polat, Bülent, additional, Hildebrandt, Guido, additional, Müller, Arndt-Christian, additional, Putora, Paul M., additional, Papachristofilou, Alexandros, additional, Hayoz, Stefanie, additional, Schär, Corinne, additional, Li, Qiyu, additional, Sumila, Marcin, additional, Zaugg, Kathrin, additional, Guckenberger, Matthias, additional, Ost, Piet, additional, Bosetti, Davide G., additional, Reuter, Christiane, additional, Gomez, Silvia, additional, Khanfir, Kaouthar, additional, Aebersold, Daniel M., additional, Ghadjar, Pirus, additional, and Pra, Alan Dal, additional

Published
2022
Full Text
View/download PDF

44. Ultrahypofractionation of localized prostate cancer

Author

Wolf, Frank, Sedlmayer, Felix, Aebersold, Daniel, Albrecht, Clemens, Böhmer, Dirk, Flentje, Michael, Ganswindt, Ute, Ghadjar, Pirus, Höcht, Stefan, Hölscher, Tobias, Müller, Arndt-Christian, Niehoff, Peter, Pinkawa, Michael, Schmidt-Hegemann, Nina-Sophie, Zamboglou, Constantinos, Zips, Daniel, and Wiegel, Thomas

Subjects
Male, Clinical Trials as Topic, SBRT, Treatment Outcome, Radiotherapy, Prostate, Hypofractionation, Humans, Prostatic Neoplasms, Radiation Dose Hypofractionation, Review Article, Extreme hypofractionation, SABR
Abstract

Due to its low fractionation sensitivity, also known as “alpha/beta ratio,” in relation to its surrounding organs at risk, prostate cancer is predestined for hypofractionated radiation schedules assuming an increased therapeutic ratio compared to normofractionated regimens. While moderate hypofractionation (2.2–4 Gy) has been proven to be non-inferior to normal fractionation in several large randomized trials for localized prostate cancer, level I evidence for ultrahypofractionation (>4 Gy) was lacking until recently. An accumulating body of non-randomized evidence has recently been strengthened by the publication of two randomized studies comparing ultrahypofractionation with a normofractionated schedule, i.e., the Scandinavian HYPO-RT trial by Widmark et al. and the first toxicity results of the PACE‑B trial. In this review, we aim to give a brief overview of the current evidence of ultrahypofractionation, make an overall assessment of the level of evidence, and provide recommendations and requirements that should be followed before introducing ultrahypofractionation into routine clinical use.

Published
2020

45. Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P)

Author

Hölscher, Tobias, primary, Baumann, Michael, additional, Kotzerke, Jörg, additional, Zöphel, Klaus, additional, Paulsen, Frank, additional, Müller, Arndt-Christian, additional, Zips, Daniel, additional, Thomas, Christian, additional, Wirth, Manfred, additional, Troost, Esther G. C., additional, Krause, Mechthild, additional, Löck, Steffen, additional, and Lohaus, Fabian, additional

Published
2022
Full Text
View/download PDF

47. First-In-Human Validation of CT-Based Proton Range Prediction Using Prompt Gamma Imaging in Prostate Cancer Treatments

Author

Berthold, Jonathan, primary, Khamfongkhruea, Chirasak, additional, Petzoldt, Johannes, additional, Thiele, Julia, additional, Hölscher, Tobias, additional, Wohlfahrt, Patrick, additional, Peters, Nils, additional, Jost, Angelina, additional, Hofmann, Christian, additional, Janssens, Guillaume, additional, Smeets, Julien, additional, and Richter, Christian, additional

Published
2021
Full Text
View/download PDF

50. Prostatakarzinom: palliative Therapie

Author

Huber, Johannes, primary, Brogsitter, Claudia, additional, Kotzerke, Jörg, additional, Hölscher, Tobias, additional, Baumann, Michael, additional, Fröhner, Michael, additional, and Wirth, Manfred, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results